Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001340494 | SCV001534307 | likely benign | Saldino-Mainzer syndrome | 2024-10-26 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001773680 | SCV001992876 | uncertain significance | not provided | 2019-07-03 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Fulgent Genetics, |
RCV002504533 | SCV002815901 | uncertain significance | Saldino-Mainzer syndrome; Retinitis pigmentosa 80 | 2024-06-20 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004035941 | SCV004885930 | uncertain significance | Inborn genetic diseases | 2024-03-01 | criteria provided, single submitter | clinical testing | The c.179G>A (p.R60K) alteration is located in exon 4 (coding exon 2) of the IFT140 gene. This alteration results from a G to A substitution at nucleotide position 179, causing the arginine (R) at amino acid position 60 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |